Euromedis Sp. z o.o.

Szczecin 70111

1 studies enrolling now · 15 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Dementia, Frontotemporal, Dementia-related Psychosis, FTD, FTD-GRN, Frontotemporal Dementia, Known or Suspected Focal Liver Lesions, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Pediatric Migraine

Studies at this site

• Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting now
• A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis — Running, not enrolling
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis — Completed
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis — Completed
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex — Completed